Our experience in viral hepatitis (VH) immunoglobulin prophylaxis

Area of Science:

• Pediatrics
• Immunology
• Hepatology

Background:

• Hepatitis Viral (VH) presents an annual autumn-winter peak in incidence among children.
• Subclinical and icteric forms of VH pose significant public health challenges.

Purpose of the Study:

• To evaluate the efficacy of standard immunoglobulins (IG) in preventing Hepatitis Viral (VH) in children.
• To compare prophylactic IG administration versus IG administration solely in response to exposure.

Main Methods:

• Two experiments involved 72,888 children, with 36,270 receiving IG and 36,618 in the control group.
• IG was administered either preventatively before the seasonal peak or post-exposure in identified foci.
• VH incidence was assessed through clinical examinations and SGPT levels.

Main Results:

• Prophylactic IG decreased icteric VH incidence by 4-14 fold and eliminated the seasonal peak, with efficacy lasting 5-6 months.
• Subclinical VH incidence was approximately 3 times lower in children receiving prophylactic IG.
• IG administration only in response to exposure did not reduce icteric VH incidence and doubled subclinical VH rates compared to controls.

Conclusions:

• Preventive immunoglobulin administration is highly effective in reducing both icteric and subclinical Hepatitis Viral (VH) in children.
• Targeted IG administration post-exposure is less effective than a prophylactic approach for controlling VH outbreaks.
• Prophylactic IG offers sustained protection against VH for up to six months, mitigating seasonal incidence peaks.